Price movement over the last 24 hours
Agilent Technologies Inc vs ProShares Ultra QQQ ETF — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while ProShares Ultra QQQ ETF trades at $90.13. The key difference: Agilent Technologies Inc pays a 0.78% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | QLD | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.20 | $100.53 |
52-Week Low | $110.24 | $57.16 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
QLD, the ProShares Ultra QQQ ETF, trades at $93.12, up 2.8% today, reflecting strong bullish momentum with a technical buy signal from moving averages. As a 2x leveraged ETF tracking the Nasdaq-100, it amplifies returns but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though it experienced significant drawdowns historically.
The outlook for QLD is tied to tech sector strength, with AI optimism and easing geopolitical tensions supporting growth. However, leveraged ETFs like QLD are high-risk tactical instruments unsuitable for long-term holdings due to daily rebalancing effects. Investors should weigh potential amplified gains against the risk of sharp declines in volatile markets.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →